Economic Value of Dengue Vaccine in Thailand

Abstract

With several candidate dengue vaccines under development, this is an important time to help stakeholders (e.g., policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics and strategies might be readily altered. We developed a decision analytic Markov simulation model to evaluate the potential health and economic value of administering a dengue vaccine to an individual (≤ 1 year of age) in Thailand from the societal perspective. Sensitivity analyses evaluated the effects of ranging various vaccine (e.g., cost, efficacy, side effect), epidemiological (dengue risk), and disease (treatment-seeking behavior) characteristics. A ≥ 50% efficacious vaccine was highly cost-effective [< 1× per capita gross domestic product (GDP) ($4,289)] up to a total vaccination cost of $60 and cost-effective [< 3× per capita GDP ($12,868)] up to a total vaccination cost of $200. When the total vaccine series was $1.50, many scenarios were cost saving.

Economic Burden of Dengue Virus Infection at the Household Level Among Residents of Puerto Maldonado, Peru

“…Similar studies are needed to improve our understanding of the burden of this disease, especially in the face of current efforts to develop a vaccine 57 and cost-effectiveness studies that may be needed to correctly assess the impact of these strategies. 35 Received November 26, 2014. Accepted for publication April 10, 2015.…”

“…A secondary objective was to describe the demographic and socioeconomic features of the population of Puerto Maldonado according to their migration status. Results from this study provide essential information on the economic burden of dengue illness at the household level, indicating the real impact on individuals and families, and help to assess the cost benefit of future vaccine efforts 15,16,[33][34][35] and continuing vector control strategies.…”

Total Economic Cost and Burden of Dengue in Nicaragua: 1996–2010

“…The costs associated with dengue infection in Nicaragua are not insignificant; these data illustrate the potential resources that could be reallocated for other pressing health concerns such as an efficacious DF vaccine intervention to be implemented in Nicaragua or the region. Previous efforts have determined the cost-effectiveness of potential dengue vaccine interventions, but few in Latin America [47][48][49] ; because there are several dengue vaccine candidates currently under development, this analysis could prove useful for key stakeholders in informing policy and decisionmaking. In the meantime, the incorporation of the costs associated with control and surveillance activities will prove useful in the assessment of current vector control programs, as these results show a discrepancy in terms of the funds budgeted for dengue prevention and control, and the total cost of disease in Nicaragua.…”

Dispersal of Male Aedes aegypti in a Coastal Village in Southern Mexico

“…aegypti. Although vaccines and therapeutics are a current focus of attention, none are currently licensed for broad scale use 6 and contemporary dengue control programs will continue to rely on vector control as the primary line of defense against virus transmission. When done properly, mosquito population control effectively prevents dengue.…”